---
document_datetime: 2025-12-02 05:20:07
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/veraseal.html
document_name: veraseal.html
version: success
processing_time: 0.1129814
conversion_datetime: 2025-12-28 19:22:05.883303
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# VeraSeal

[RSS](/en/individual-human-medicine.xml/66736)

##### Authorised

This medicine is authorised for use in the European Union

human fibrinogen / human thrombin Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on VeraSeal](#news-on)
- [More information on VeraSeal](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

VeraSeal is a sealant (glue) used to stop bleeding during surgery or to support stitches during surgery on blood vessels.

VeraSeal is used when standard surgical techniques do not work well enough. It contains the active substances human fibrinogen and human thrombin.

Expand section

Collapse section

## How is VeraSeal used?

VeraSeal should only be used by an experienced surgeon who has been trained in its use. It is available as two prefilled syringes in a syringe holder, one containing a solution of human fibrinogen, and the other containing a solution of human thrombin. Before use, the syringes are attached to a device supplied with the medicine that allows their contents to mix as they are dripped or sprayed on the wound. The amount of VeraSeal to be used depends on a number of factors, including the type of surgery, the size of the wound and the number of applications.

## How does VeraSeal work?

The active substances in VeraSeal, fibrinogen and thrombin, are proteins present in human plasma (the liquid part of the blood), which are involved in the blood clotting process.

When the two active substances are mixed, thrombin cuts fibrinogen up into fibrin (protein involved in forming blood clots in the body). The fibrin then aggregates (sticks together) and forms a fibrin clot that helps the wound to heal, preventing bleeding.

## What benefits of VeraSeal have been shown in studies?

Three main studies in 614 patients, mainly adults, found that VeraSeal is effective at stopping bleeding within 4 minutes of applying it during surgery.

In one study of blood vessel surgery, VeraSeal worked better than manual compression, with 76% of patients having no bleeding 4 minutes after treatment with VeraSeal (83 out of 109), compared with 23% after manual compression (13 out of 57).

In a second study of organ surgery, VeraSeal was as effective as another product Surgicel: 93% of the patients had no bleeding 4 minutes after treatment with VeraSeal (103 out of 111), while 81% of the patients had no bleeding with Surgicel (91 out of 113).

In a third study of soft tissue surgery, VeraSeal was as effective as Surgicel: 83% of the patients had no bleeding 4 minutes after treatment with VeraSeal (96 out of 116), compared with 78% of the patients after treatment with Surgicel (84 out of 108).

A fourth study was carried out in 178 children and adolescents who received either VeraSeal or another medicine containing fibrinogen and thrombin (Evicel) to stop bleeding during surgery. In this study, 97% (88 out of 91) of patients given VeraSeal had no bleeding 4 minutes after treatment and no new bleeding requiring treatment until the end of the surgery, compared with 95% (83 out of 87) of patients given Evicel.

## What are the risks associated with VeraSeal?

For the full list of side effects and restrictions with VeraSeal, see the package leaflet.

The most common side effects with VeraSeal (which may affect up to 1 in 10 people) include nausea (feeling sick), pruritus (itchiness) and procedural pain (pain from the surgery). Rarely, VeraSeal may cause an allergic reaction which can be severe especially when the medicine is used repeatedly. In rare cases, patients may develop antibodies to the proteins in VeraSeal, which could interfere with blood clotting. Thromboembolic complications (blood clots) may occur if VeraSeal is accidentally injected into a blood vessel.

VeraSeal must not be used intravascularly (inside blood vessels) or to treat heavy bleeding of the arteries.

## Why is VeraSeal authorised in the EU?

VeraSeal has been shown to effectively stop bleeding during surgery, which can be expected to reduce blood loss, reduce time in the operating theatre and possibly shorten hospital stays. Although patients could develop antibodies against the medicine, which might reduce its effectiveness, this has not been seen in the studies.

The observed side effects were as expected with major surgeries or the patient's condition. The European Medicines Agency therefore decided that VeraSeal's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of VeraSeal?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of VeraSeal have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of VeraSeal are continuously monitored. Side effects reported with VeraSeal are carefully evaluated and any necessary action taken to protect patients.

## Other information about VeraSeal

VeraSeal received a marketing authorisation valid throughout the EU on 10 November 2017.

VeraSeal : EPAR - Medicine overview

Reference Number: EMA/580809/2023

English (EN) (112.08 KB - PDF)

**First published:** 17/01/2018

**Last updated:** 05/03/2024

[View](/en/documents/overview/veraseal-epar-medicine-overview_en.pdf)

[Other languages (21)](#file-language-dropdown-493)

български (BG) (135.78 KB - PDF)

**First published:**

17/01/2018

**Last updated:**

05/03/2024

[View](/bg/documents/overview/veraseal-epar-medicine-overview_bg.pdf)

español (ES) (112.24 KB - PDF)

**First published:**

17/01/2018

**Last updated:**

05/03/2024

[View](/es/documents/overview/veraseal-epar-medicine-overview_es.pdf)

čeština (CS) (135.59 KB - PDF)

**First published:**

17/01/2018

**Last updated:**

05/03/2024

[View](/cs/documents/overview/veraseal-epar-medicine-overview_cs.pdf)

dansk (DA) (110.88 KB - PDF)

**First published:**

17/01/2018

**Last updated:**

05/03/2024

[View](/da/documents/overview/veraseal-epar-medicine-overview_da.pdf)

Deutsch (DE) (114.9 KB - PDF)

**First published:**

17/01/2018

**Last updated:**

05/03/2024

[View](/de/documents/overview/veraseal-epar-medicine-overview_de.pdf)

eesti keel (ET) (109.49 KB - PDF)

**First published:**

17/01/2018

**Last updated:**

05/03/2024

[View](/et/documents/overview/veraseal-epar-medicine-overview_et.pdf)

ελληνικά (EL) (135.27 KB - PDF)

**First published:**

17/01/2018

**Last updated:**

05/03/2024

[View](/el/documents/overview/veraseal-epar-medicine-overview_el.pdf)

hrvatski (HR) (134.13 KB - PDF)

**First published:**

17/01/2018

**Last updated:**

05/03/2024

[View](/hr/documents/overview/veraseal-epar-medicine-overview_hr.pdf)

italiano (IT) (111.3 KB - PDF)

**First published:**

17/01/2018

**Last updated:**

05/03/2024

[View](/it/documents/overview/veraseal-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (150.64 KB - PDF)

**First published:**

17/01/2018

**Last updated:**

05/03/2024

[View](/lv/documents/overview/veraseal-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (133.44 KB - PDF)

**First published:**

17/01/2018

**Last updated:**

05/03/2024

[View](/lt/documents/overview/veraseal-epar-medicine-overview_lt.pdf)

magyar (HU) (134.44 KB - PDF)

**First published:**

17/01/2018

**Last updated:**

05/03/2024

[View](/hu/documents/overview/veraseal-epar-medicine-overview_hu.pdf)

Malti (MT) (137.43 KB - PDF)

**First published:**

17/01/2018

**Last updated:**

05/03/2024

[View](/mt/documents/overview/veraseal-epar-medicine-overview_mt.pdf)

Nederlands (NL) (111.55 KB - PDF)

**First published:**

17/01/2018

**Last updated:**

05/03/2024

[View](/nl/documents/overview/veraseal-epar-medicine-overview_nl.pdf)

polski (PL) (136.43 KB - PDF)

**First published:**

17/01/2018

**Last updated:**

05/03/2024

[View](/pl/documents/overview/veraseal-epar-medicine-overview_pl.pdf)

português (PT) (113.11 KB - PDF)

**First published:**

17/01/2018

**Last updated:**

05/03/2024

[View](/pt/documents/overview/veraseal-epar-medicine-overview_pt.pdf)

română (RO) (132.53 KB - PDF)

**First published:**

17/01/2018

**Last updated:**

05/03/2024

[View](/ro/documents/overview/veraseal-epar-medicine-overview_ro.pdf)

slovenčina (SK) (134.36 KB - PDF)

**First published:**

17/01/2018

**Last updated:**

05/03/2024

[View](/sk/documents/overview/veraseal-epar-medicine-overview_sk.pdf)

slovenščina (SL) (132.32 KB - PDF)

**First published:**

17/01/2018

**Last updated:**

05/03/2024

[View](/sl/documents/overview/veraseal-epar-medicine-overview_sl.pdf)

Suomi (FI) (109.62 KB - PDF)

**First published:**

17/01/2018

**Last updated:**

05/03/2024

[View](/fi/documents/overview/veraseal-epar-medicine-overview_fi.pdf)

svenska (SV) (110.32 KB - PDF)

**First published:**

17/01/2018

**Last updated:**

05/03/2024

[View](/sv/documents/overview/veraseal-epar-medicine-overview_sv.pdf)

VeraSeal : EPAR - Risk management plan

English (EN) (1.29 MB - PDF)

**First published:** 06/01/2020

**Last updated:** 05/03/2024

[View](/en/documents/rmp/veraseal-epar-risk-management-plan_en.pdf)

## Product information

VeraSeal : EPAR - Product information

English (EN) (1.84 MB - PDF)

**First published:** 17/01/2018

**Last updated:** 27/03/2025

[View](/en/documents/product-information/veraseal-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-382)

български (BG) (883.6 KB - PDF)

**First published:**

17/01/2018

**Last updated:**

27/03/2025

[View](/bg/documents/product-information/veraseal-epar-product-information_bg.pdf)

español (ES) (1.88 MB - PDF)

**First published:**

17/01/2018

**Last updated:**

27/03/2025

[View](/es/documents/product-information/veraseal-epar-product-information_es.pdf)

čeština (CS) (1.33 MB - PDF)

**First published:**

17/01/2018

**Last updated:**

27/03/2025

[View](/cs/documents/product-information/veraseal-epar-product-information_cs.pdf)

dansk (DA) (1.24 MB - PDF)

**First published:**

17/01/2018

**Last updated:**

27/03/2025

[View](/da/documents/product-information/veraseal-epar-product-information_da.pdf)

Deutsch (DE) (1.75 MB - PDF)

**First published:**

17/01/2018

**Last updated:**

27/03/2025

[View](/de/documents/product-information/veraseal-epar-product-information_de.pdf)

eesti keel (ET) (1.52 MB - PDF)

**First published:**

17/01/2018

**Last updated:**

27/03/2025

[View](/et/documents/product-information/veraseal-epar-product-information_et.pdf)

ελληνικά (EL) (1.73 MB - PDF)

**First published:**

17/01/2018

**Last updated:**

27/03/2025

[View](/el/documents/product-information/veraseal-epar-product-information_el.pdf)

français (FR) (1.72 MB - PDF)

**First published:**

17/01/2018

**Last updated:**

27/03/2025

[View](/fr/documents/product-information/veraseal-epar-product-information_fr.pdf)

hrvatski (HR) (1.4 MB - PDF)

**First published:**

17/01/2018

**Last updated:**

27/03/2025

[View](/hr/documents/product-information/veraseal-epar-product-information_hr.pdf)

íslenska (IS) (1.67 MB - PDF)

**First published:**

17/01/2018

**Last updated:**

27/03/2025

[View](/is/documents/product-information/veraseal-epar-product-information_is.pdf)

italiano (IT) (932.69 KB - PDF)

**First published:**

17/01/2018

**Last updated:**

27/03/2025

[View](/it/documents/product-information/veraseal-epar-product-information_it.pdf)

latviešu valoda (LV) (1.33 MB - PDF)

**First published:**

17/01/2018

**Last updated:**

27/03/2025

[View](/lv/documents/product-information/veraseal-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.68 MB - PDF)

**First published:**

17/01/2018

**Last updated:**

27/03/2025

[View](/lt/documents/product-information/veraseal-epar-product-information_lt.pdf)

magyar (HU) (1.64 MB - PDF)

**First published:**

17/01/2018

**Last updated:**

27/03/2025

[View](/hu/documents/product-information/veraseal-epar-product-information_hu.pdf)

Malti (MT) (1.73 MB - PDF)

**First published:**

17/01/2018

**Last updated:**

27/03/2025

[View](/mt/documents/product-information/veraseal-epar-product-information_mt.pdf)

Nederlands (NL) (1.64 MB - PDF)

**First published:**

17/01/2018

**Last updated:**

27/03/2025

[View](/nl/documents/product-information/veraseal-epar-product-information_nl.pdf)

norsk (NO) (1.37 MB - PDF)

**First published:**

17/01/2018

**Last updated:**

27/03/2025

[View](/no/documents/product-information/veraseal-epar-product-information_no.pdf)

polski (PL) (1.69 MB - PDF)

**First published:**

17/01/2018

**Last updated:**

27/03/2025

[View](/pl/documents/product-information/veraseal-epar-product-information_pl.pdf)

português (PT) (1.67 MB - PDF)

**First published:**

17/01/2018

**Last updated:**

27/03/2025

[View](/pt/documents/product-information/veraseal-epar-product-information_pt.pdf)

română (RO) (1.57 MB - PDF)

**First published:**

17/01/2018

**Last updated:**

27/03/2025

[View](/ro/documents/product-information/veraseal-epar-product-information_ro.pdf)

slovenčina (SK) (1.74 MB - PDF)

**First published:**

17/01/2018

**Last updated:**

27/03/2025

[View](/sk/documents/product-information/veraseal-epar-product-information_sk.pdf)

slovenščina (SL) (1.67 MB - PDF)

**First published:**

17/01/2018

**Last updated:**

27/03/2025

[View](/sl/documents/product-information/veraseal-epar-product-information_sl.pdf)

Suomi (FI) (1.65 MB - PDF)

**First published:**

17/01/2018

**Last updated:**

27/03/2025

[View](/fi/documents/product-information/veraseal-epar-product-information_fi.pdf)

svenska (SV) (1.62 MB - PDF)

**First published:**

17/01/2018

**Last updated:**

27/03/2025

[View](/sv/documents/product-information/veraseal-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0000255532 27/03/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

VeraSeal : EPAR - All Authorised presentations

English (EN) (19.53 KB - PDF)

**First published:** 17/01/2018

**Last updated:** 17/01/2018

[View](/en/documents/all-authorised-presentations/veraseal-epar-all-authorised-presentations_en.pdf)

[Other languages (23)](#file-language-dropdown-334)

български (BG) (39.27 KB - PDF)

**First published:**

17/01/2018

**Last updated:**

17/01/2018

[View](/bg/documents/all-authorised-presentations/veraseal-epar-all-authorised-presentations_bg.pdf)

español (ES) (21.64 KB - PDF)

**First published:**

17/01/2018

**Last updated:**

17/01/2018

[View](/es/documents/all-authorised-presentations/veraseal-epar-all-authorised-presentations_es.pdf)

čeština (CS) (34.28 KB - PDF)

**First published:**

17/01/2018

**Last updated:**

17/01/2018

[View](/cs/documents/all-authorised-presentations/veraseal-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (21.7 KB - PDF)

**First published:**

17/01/2018

**Last updated:**

17/01/2018

[View](/da/documents/all-authorised-presentations/veraseal-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (21.67 KB - PDF)

**First published:**

17/01/2018

**Last updated:**

17/01/2018

[View](/de/documents/all-authorised-presentations/veraseal-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (15.96 KB - PDF)

**First published:**

17/01/2018

**Last updated:**

17/01/2018

[View](/et/documents/all-authorised-presentations/veraseal-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (37.59 KB - PDF)

**First published:**

17/01/2018

**Last updated:**

17/01/2018

[View](/el/documents/all-authorised-presentations/veraseal-epar-all-authorised-presentations_el.pdf)

français (FR) (21.47 KB - PDF)

**First published:**

17/01/2018

**Last updated:**

17/01/2018

[View](/fr/documents/all-authorised-presentations/veraseal-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (38.21 KB - PDF)

**First published:**

17/01/2018

**Last updated:**

17/01/2018

[View](/hr/documents/all-authorised-presentations/veraseal-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (16.2 KB - PDF)

**First published:**

17/01/2018

**Last updated:**

17/01/2018

[View](/is/documents/all-authorised-presentations/veraseal-epar-all-authorised-presentations_is.pdf)

latviešu valoda (LV) (48.13 KB - PDF)

**First published:**

17/01/2018

**Last updated:**

17/01/2018

[View](/lv/documents/all-authorised-presentations/veraseal-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (33.42 KB - PDF)

**First published:**

17/01/2018

**Last updated:**

17/01/2018

[View](/lt/documents/all-authorised-presentations/veraseal-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (32.2 KB - PDF)

**First published:**

17/01/2018

**Last updated:**

17/01/2018

[View](/hu/documents/all-authorised-presentations/veraseal-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (32.91 KB - PDF)

**First published:**

17/01/2018

**Last updated:**

17/01/2018

[View](/mt/documents/all-authorised-presentations/veraseal-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (21.18 KB - PDF)

**First published:**

17/01/2018

**Last updated:**

17/01/2018

[View](/nl/documents/all-authorised-presentations/veraseal-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (21.62 KB - PDF)

**First published:**

17/01/2018

**Last updated:**

17/01/2018

[View](/no/documents/all-authorised-presentations/veraseal-epar-all-authorised-presentations_no.pdf)

polski (PL) (35.55 KB - PDF)

**First published:**

17/01/2018

**Last updated:**

17/01/2018

[View](/pl/documents/all-authorised-presentations/veraseal-epar-all-authorised-presentations_pl.pdf)

português (PT) (21.79 KB - PDF)

**First published:**

17/01/2018

**Last updated:**

17/01/2018

[View](/pt/documents/all-authorised-presentations/veraseal-epar-all-authorised-presentations_pt.pdf)

română (RO) (34.62 KB - PDF)

**First published:**

17/01/2018

**Last updated:**

17/01/2018

[View](/ro/documents/all-authorised-presentations/veraseal-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (35.39 KB - PDF)

**First published:**

17/01/2018

**Last updated:**

17/01/2018

[View](/sk/documents/all-authorised-presentations/veraseal-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (23.14 KB - PDF)

**First published:**

17/01/2018

**Last updated:**

17/01/2018

[View](/sl/documents/all-authorised-presentations/veraseal-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (22.77 KB - PDF)

**First published:**

17/01/2018

**Last updated:**

17/01/2018

[View](/fi/documents/all-authorised-presentations/veraseal-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (16.08 KB - PDF)

**First published:**

17/01/2018

**Last updated:**

17/01/2018

[View](/sv/documents/all-authorised-presentations/veraseal-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine VeraSeal Active substance human fibrinogen, human thrombin International non-proprietary name (INN) or common name

- human fibrinogen
- human thrombin

Therapeutic area (MeSH) Hemostasis, Surgical Anatomical therapeutic chemical (ATC) code B02BC

### Pharmacotherapeutic group

Antihemorrhagics

### Therapeutic indication

Supportive treatment in adults where standard surgical techniques are insufficient:

- for improvement of haemostasis
- as suture support in vascular surgery

## Authorisation details

EMA product number EMEA/H/C/004446 Marketing authorisation holder

Instituto Grifols, S.A.

Poligono Levante

Opinion adopted 14/09/2017 Marketing authorisation issued 10/11/2017 Revision 10

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

VeraSeal : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (141.92 KB - PDF)

**First published:** 27/03/2025

[View](/en/documents/procedural-steps-after/veraseal-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

VeraSeal : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (139.78 KB - PDF)

**First published:** 06/01/2020

**Last updated:** 27/03/2025

[View](/en/documents/procedural-steps-after/veraseal-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

VeraSeal-H-C-004446-II-0027 : EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/56893/2024

English (EN) (3.96 MB - PDF)

**First published:** 05/03/2024

[View](/en/documents/variation-report/veraseal-h-c-004446-ii-0027-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for VeraSeal (II-27)

Adopted

Reference Number: EMA/539247/2023

English (EN) (120.26 KB - PDF)

**First published:** 15/12/2023

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-veraseal-ii-27_en.pdf)

## Initial marketing authorisation documents

VeraSeal : EPAR - Public assessment report

Reference Number: EMA/734511/2017

English (EN) (3.54 MB - PDF)

**First published:** 17/01/2018

**Last updated:** 17/01/2018

[View](/en/documents/assessment-report/veraseal-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for VeraSeal

Reference Number: EMA/CHMP/586635/2017

English (EN) (72.1 KB - PDF)

**First published:** 15/09/2017

**Last updated:** 15/09/2017

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-veraseal_en.pdf)

#### News on VeraSeal

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 December 2023](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-11-14-december-2023) 15/12/2023

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11 to 14 September 2017](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-11-14-september-2017) 15/09/2017

#### More information on VeraSeal

- [EMEA-001598-PIP01-13-M03 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001598-pip01-13-m03)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 27/03/2025

## Share this page

[Back to top](#main-content)